NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 129 filers reported holding NOVOCURE LTD in Q4 2017. The put-call ratio across all filers is 0.22 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $7,302,000 | -29.7% | 115,479 | -46.4% | 11.05% | +122.0% |
| Q1 2019 | $10,380,000 | -25.4% | 215,479 | -48.1% | 4.98% | -74.0% |
| Q4 2018 | $13,910,000 | -36.1% | 415,479 | 0.0% | 19.11% | -12.0% |
| Q3 2018 | $21,771,000 | -19.6% | 415,479 | -52.0% | 21.72% | -24.4% |
| Q2 2018 | $27,089,000 | -9.0% | 865,479 | -36.6% | 28.71% | +31.1% |
| Q1 2018 | $29,767,000 | -8.8% | 1,365,479 | -15.5% | 21.90% | -3.7% |
| Q4 2017 | $32,632,000 | +1.8% | 1,615,479 | 0.0% | 22.75% | +7.3% |
| Q3 2017 | $32,067,000 | +2.1% | 1,615,479 | -11.0% | 21.20% | +11.2% |
| Q2 2017 | $31,407,000 | +113.6% | 1,815,479 | 0.0% | 19.07% | +17.4% |
| Q1 2017 | $14,705,000 | +3.2% | 1,815,479 | 0.0% | 16.24% | -6.0% |
| Q4 2016 | $14,251,000 | -8.1% | 1,815,479 | 0.0% | 17.28% | -10.3% |
| Q3 2016 | $15,504,000 | -26.8% | 1,815,479 | 0.0% | 19.27% | -26.8% |
| Q2 2016 | $21,186,000 | -19.4% | 1,815,479 | 0.0% | 26.31% | -28.1% |
| Q1 2016 | $26,288,000 | – | 1,815,479 | – | 36.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $24,386,000 | 14.72% |
| HARTLINE INVESTMENT CORP/ | 335,191 | $58,001,000 | 8.32% |
| Deep Track Capital, LP | 1,341,300 | $93,220,000 | 6.13% |
| MORGAN JESS S & CO INC | 48,345 | $3,360,000 | 3.48% |
| Taylor Frigon Capital Management LLC | 68,908 | $4,789,000 | 2.49% |
| HighVista Strategies LLC | 28,007 | $1,946,000 | 1.18% |
| Private Harbour Investment Management & Counsel, LLC | 13,106 | $911,000 | 1.01% |
| Lloyd Park, LLC | 9,325 | $648,000 | 0.68% |
| Baillie Gifford | 9,116,230 | $633,578,000 | 0.65% |
| HAP Trading, LLC | 110,900 | $10,575,000 | 0.53% |